Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecas120066-54-8

120066-54-8

120066-54-8 structural image
Product Name: Gadoteridol
Formula: C17H28GdN4O7
Synonyms:
Inquiry

CHEMICAL AND PHYSICAL PROPERTIES

Color/Form White solid obtained as an aggregate clump of fine needle-like micro-crystals from methanol/acetone
Melting Point >225 °C
Solubility In water, 737 mg/mL
Density Osmolality (37 °C): 630 mOsM/kg water; viscosity (cP): 2.0 (20 °C), 1.3 (37 °C); density at 25 °C 1.140. /Gadoteridol injection/
LogP log Kow = -3.68 (octanol/water); logP = -1.98 (butanol/water), at pH 7
Other Experimental Properties Hydrophilic

COMPUTED DESCRIPTORS

Molecular Weight 558.7 g/mol
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 11
Rotatable Bond Count 5
Exact Mass 559.12774 g/mol
Monoisotopic Mass 559.12774 g/mol
Topological Polar Surface Area 154 Ų
Heavy Atom Count 29
Formal Charge 0
Complexity 471
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 1
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 2
Compound Is Canonicalized Yes

PRODUCT INTRODUCTION

description

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.

RELATED SUPPLIERS

Laksh Finechem Pvt.Ltd.

1Y
product:120066-54-8 Gadoteridol 99%

Rivashaa Agrotech Biopharma Pvt. Ltd.

1Y
product:120066-54-8 98%

Biophore India Pharmaceuticals Pvt Ltd

1Y
product:Gadoteridol 98%

Blue Jet Healthcare Ltd

1Y
product:Gadoteridol >98%
All suppliers(4)